CNE100004NS2
CNE100004NS2
GUOBANG PHARMA LTD
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 13.54B EUR | 11.58B EUR | 14.52B EUR | 13.86B EUR |
Enterprise Value | 11.88B EUR | 11.16B EUR | 14.01B EUR | 13.39B EUR |
Valuation Multiples | ||||
Trailing P/E | 19.02x | 23.54x | 26.32x | 22.86x |
Forward P/E | -- | -- | -- | -- |
Price to Sales | 2.21x | 2.47x | 3.12x | 3.03x |
Price to Book | 1.59x | 1.38x | 1.67x | 1.62x |
EV/Revenue | 1.94x | 2.38x | 3.01x | 2.93x |
EV/EBITDA | 9.11x | 18.94x | 20.57x | 18.36x |
Price to FCF (P/FCF) | 26.28x | 42.81x | 24.87x | 154.82x |
EV/FCF | 23.05x | 41.27x | 23.98x | 149.58x |
FCF Yield | 3.81% | 2.34% | 4.02% | 0.65% |